Key component of inflammatory microenvironment and tumor

doi:10.3760/cma.j.issn.1673-422X.2014.03.003

Abstract

Abstract: Tumor microenvironment mainly consists of cancer cells, tumor associated fibroblasts, tumor associated macrophages, extracellular matrix and so on. The occurrence and development, recurrence and metastasis of cancer are closely related with its inflammatory microenvironment aroud. Many researches demonstrate that inflammatory induce the development of tumor, and at the same time it is always existed in the process of the progression of tumor. The mainly components of microenviroment have complex molecule network relationships with each other. Interdicting or disturbing one or several link of their relationships will contribute to the preventment of malignant phenotype and prognosis of cancer cells.

Key words: Neoplasms, Cytokines, Extracellular matrix, Inflammatory microenvironment

HE Xue-Qun, HAN Ke-Qi. Key component of inflammatory microenvironment and tumor[J]. Journal of International Oncology, 2014, 41(3): 169-172.

References

［1］ Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］.Cell, 2011, 144(5)： 646-674. ［2］ Grivennikov SI, Greten FR, Karin M. Immunity,inflammation, and cancer［J］. Cell, 2010, 140(6): 883-899. ［3］ Bao B, Thakur A, Li Y, et al. The immunological contribution of NFκB within the tumor microenvironment: A potential protective role of zinc as an antitumor agent［J］. Biochim Biophy Acta, 2012, 1825(2):160-172. ［4］ Wu X, Chen X, Zhou Q, et al. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer［J］.Cancer Lett, 2013, 335(1):128-135. ［5］ Jedeszko C, Victor BC, Podgorski I, et al. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ［J］. Cancer Res, 2009, 69(23):91489155. ［6］ Rasanen K, Vaheri A. Activation of fibroblasts in cancer stroma［J］. Exp Cell Res, 2010, 316(17):2713-2722. ［7］ Matsumoto K, Nakamura T, Sakai K, et al. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4［J］. Proteomics, 2008, 8(16):3360-3370. ［8］ Suzuki Y, Sakai K, Ueki J, et al. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma［J］. Int J Cancer, 2010, 127(8):1948-1957. ［9］ Sakaguchi S,Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance［J］. Cell, 2008, 133(5):775-787. ［10］ Smith TR, Kumar V. Revival of CD8+ Tregmediated suppression［J］. Trends Immunol, 2008, 29(7):337-342. ［11］ Terme M, Chaput N, Combadiere B, et al. Regulatory T cells control dendritic cell/NK cell crosstalk in lymph nodes at the steady state by inhibiting CD4+ selfreactive T cells［J］. J Immunol， 2008， 180(7):4679-4686. ［12］ Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostateinfiltrating lymphocytes reveals TH17 and Treg skewing［J］. Clin Cancer Res, 2008, 14(11):3254-3261. ［13］ Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets［J］. Semin Cancer Biol, 2011, 21(1):35-43. ［14］ Marigo I, Dolcetti L, Serafini P, et al. Tumorinduced tolerance and immune suppression by myeloid derived suppressor cells［J］. Immunol Rev, 2008, 222:162-179. ［15］ Gabrilovich DI, Nagaraj S. Myeloidderived suppressor cells as regulators of the immune system［J］. Nat Rev Immunol, 2009, 9(3):162-174. ［16］ Gabrilovich DI, Nagaraj S. Myeloidderived suppressor cells as regulators of the immune system［J］. Nat Rev Immunol, 2009, 9(3):162-174. ［17］ Nagaraj S, Gabrilovich DI. Myeloidderived suppressor cells in human cancer［J］. Cancer J, 2010, 16(4):348-353. ［18］ Serafini P, Mgebroff S, Noonan K, et al. Myeloidderived suppressor cells promote crosstolerance in B-cell lymphoma by expanding regulatory T cells［J］. Cancer Res, 2008, 68(13):5439-5449. ［19］ Arjaans M, Oude Munnink TH, TimmerBosscha H, et al.Transforming growth factor (TGF)β expression and activation mechanisms as potential targets for antitumor therapy and tumor imaging［J］. Pharmacol Ther, 2012, 135(2):123-132. ［20］ Curran CS, Keely PJ. Breast tumor and stromal cell responses to TGFβ and hypoxia in matrix deposition［J］. Matrix Biol, 2013, 32(2):95-105. ［21］ Wang X, Belguise K, O′Neill CF, et al. RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1［J］. Mol Cell Biol, 2009, 29(14):3832-3844. ［22］ Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription3, inflammation, and cancer: how intimate is the relationship?［J］. Ann NY Acad Sci, 2009,1171:59-76. ［23］ Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment［J］. Cancer Cell, 2011, 19(4):429-431.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.